Search clinical trials for: Ponatinib

Total 86 results

University of Colorado, Denver
Ariad Pharmaceuticals

Completed

Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Limited Stage Small Cell Lung Cancer | Adenocarcinoma of the Lung

United States
Radius Health, Inc.
Medpace, Inc.

Completed

Study to Evaluate and Compare the PK Profiles of Abaloparatide-SC and Abaloparatide-sMTS in a Cohort of Healthy Men and Healthy Women.

Healthy Volunteers

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Active, not recruiting

Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib

Chronic Myeloid Leukemia | Adults | Chronic Phase

Italy
Mesoblast International Sàrl
University of Southern California; OrthoIndy; TRIA Orthopaedic Center; Midwest... and other collaborators

Completed

A Phase I/II Study of Chondrogen Delivered by Intra-Articular Injection Following Meniscectomy

Recovery Following Partial Medial Meniscectomy

United States
Incyte Corporation

Completed

Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia. (LAL1811)

Acute Lymphoblastic Leukemia | BCR-ABL Positive | Philadelphia Positive

Italy
Ariad Pharmaceuticals

Terminated

A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia (OPTIC-2L)

Chronic Phase Chronic Myeloid Leukemia

Belgium
OHSU Knight Cancer Institute
National Cancer Institute (NCI); Oregon Health and Science University

Terminated

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia

United States
National Institute of Allergy and Infectious Diseases...
Glaxo Wellcome

Completed

Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease in Patients With AIDS: Open Label Pilot Study of Topical Trifluridine

HIV Infections | Herpes Simplex

United States
Antonio Fojo
Millennium Pharmaceuticals, Inc.

Withdrawn

Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer

Medullary Thyroid Cancer
Ariad Pharmaceuticals

Completed

Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL) (PACE)

Chronic Myeloid Leukemia | Ph+ Acute Lymphoblastic Leukemia

France, Belgium, Australia, Singapore, Germany, Spain, United Kingdom, Netherlands, Italy, Korea, Republic of, Sweden
Mayo Clinic
National Cancer Institute (NCI)

Completed

Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions

Malignant Hepatobiliary Neoplasm

United States
Versailles Hospital

Active, not recruiting

Ponatinib for FLT3-ITD Acute Myelogenous Leukemia (PONATINIB-AML)

Acute Myeloid Lukemia

France
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Completed

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia

United States
Massachusetts General Hospital

Completed

Ponatinib in Advanced NSCLC w/ RET Translocations

Non Small Cell Lung Cancer

United States
National Taiwan University Hospital

Completed

eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs

Hepatitis C | Viral Hepatitis C | Renal Disease

Taiwan
Oregon Health and Science University

Unknown

Vascular Cardiotoxicity of Ponatinib

Cardiotoxicity

United States
Wake Forest University

Completed

Clinical Trial to Evaluate Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy

Actinic Keratosis

United States
Incyte Biosciences International Sàrl

Withdrawn

A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"

BCR-ABL Positive Acute Lymphoblastic Leukemia

Germany, France, Czechia
Dana-Farber Cancer Institute

Completed

Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma

Glioblastoma

United States
Ariad Pharmaceuticals

Completed

A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)

GIST

United States
Ariad Pharmaceuticals

Completed

Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies

Chronic Myelogenous Leukemia | Hematologic Malignancies

United States
Ariad Pharmaceuticals

Approved for marketing

Expanded Access Program of Ponatinib

Chronic Myeloid Leukemia (CML) | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

United States
Nanfang Hospital of Southern Medical University

Unknown

Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia

Leukemia, Lymphoblastic, Acute

China
M.D. Anderson Cancer Center
Ariad Pharmaceuticals

Withdrawn

Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)

Leukemia | FLT3-Mutated Acute Myeloid Leukemia | FLT3-Mutated High-Risk Myelodysplastic Syndrome
Sebastian Bauer
Hannover Medical School; University Hospital Tuebingen; Universitätsmedizin Mannheim and other collaborators

Unknown

POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST (POETIG)

GIST, Malignant | KIT Gene Mutation | KIT Exon 13 Mutation

Germany
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Terminated

Ponatinib for Advanced Medullary Thyroid Cancer

Thyroid Neoplasms

United States
Hospices Civils de Lyon

Completed

Comparative Evaluation of Results of Allogeneic Hematopoietic Stem Cells Versus Ponatinib in CML Patients Carrying a Mutation T315I

Leukemia

France
Tesaro, Inc.

Withdrawn

A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)

Lymphoma | Mantle-Cell
Washington University School of Medicine

Withdrawn

Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma

Endometrial Neoplasms
Dana-Farber Cancer Institute

Terminated

Ponatinib for Squamous Cell Lung and Head and Neck Cancers

Non-Small Cell Lung Cancer, Head and Neck Cancer

United States
Ariad Pharmaceuticals

Terminated

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Chronic Myeloid Leukemia

United States, Australia, Austria, Belgium, Canada, Czech Republic, Finland, France, Germany, Hong Kong, Italy, Korea, Republic of, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, Slovakia, Spain, Sweden, Switz... and more
Eisai Co., Ltd.

Completed

Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women

Postmenopausal Osteoporosis

China
OHSU Knight Cancer Institute
Ariad Pharmaceuticals

No longer available

Compassionate Use Ponatinib

Chronic Myeloid Leukemia | Philadelphia Chromosome Positive (Ph+) Leukemias

United States
Lahey Clinic

Withdrawn

Pilot Study To Evaluate A Pharmacologically Active Nasal Sponge Following Endoscopic Sinus Surgery

Chronic Sinusitis | Sinusitis

United States
Alcon Research

Completed

Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis

Allergic Conjunctivitis
Azienda Ospedaliera V. Cervello

Unknown

Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies (IFNRIBAHE)

Hemoglobinopathies

Italy

Search clinical trials for: Ponatinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations